Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Total Liabilities (2016 - 2025)

Ocular Therapeutix has reported Total Liabilities over the past 13 years, most recently at $153.7 million for Q4 2025.

  • Quarterly results put Total Liabilities at $153.7 million for Q4 2025, up 7.82% from a year ago — trailing twelve months through Dec 2025 was $153.7 million (up 7.82% YoY), and the annual figure for FY2025 was $153.7 million, up 7.82%.
  • Total Liabilities for Q4 2025 was $153.7 million at Ocular Therapeutix, up from $152.7 million in the prior quarter.
  • Over the last five years, Total Liabilities for OCUL hit a ceiling of $160.9 million in Q4 2023 and a floor of $107.3 million in Q2 2022.
  • Median Total Liabilities over the past 5 years was $138.9 million (2024), compared with a mean of $134.8 million.
  • Peak annual rise in Total Liabilities hit 91.14% in 2021, while the deepest fall reached 37.08% in 2021.
  • Ocular Therapeutix's Total Liabilities stood at $116.9 million in 2021, then decreased by 2.55% to $113.9 million in 2022, then surged by 41.28% to $160.9 million in 2023, then dropped by 11.4% to $142.6 million in 2024, then grew by 7.82% to $153.7 million in 2025.
  • The last three reported values for Total Liabilities were $153.7 million (Q4 2025), $152.7 million (Q3 2025), and $145.4 million (Q2 2025) per Business Quant data.